New Vaccine Reduces Recurrent Urinary Tract Infections in Women
Results from the first North American Clinical Experience Study provides further evidence of MV140 safety and efficacy. Red Leaf Medical (RLM) announced that results from the first North American clinical evidence for MV 140, a sublingual vaccine for the prevention of recurrent urinary tract infections (rUTI) in women, were published in the Canadian Urological Association Journal (February 2024).
MV140 Vaccine for Recurrent Urinary Tract Infections in the News
The Globe and Mail and CTV News recently published reports indicating that MV140, Red Leaf Medical’s sublingual vaccine for the prevention of recurrent urinary tract infections in women, is awaiting Health Canada approval. The news items explain the impact of UTIs on women’s health and how the antibiotics used to treat them are contributing to antimicrobial resistance. Read the online CTV story here and watch the video of the story that aired on their broadcast here. The Globe and Mail article was published on February 27, 2023.
Red Leaf Medical Files for Approval of UROMUNE™ in Canada
Red Leaf Medical has filed a new drug submission with Health Canada for approval of UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections(rUTIs) in women. The new drug submission is supported by results from a UROMUNE™ multicenter, prospective, randomized, double-blind, placebo-controlled trial. These results were recently published in the New England Journal of Medicine Evidence.
Uromune™ Multicentre Study Published In NEJM Evidence
Red Leaf Medical is pleased to announce that results from a multicenter randomized placebo-controlled trial of UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections in women, were published online in the New England Journal of Medicine Evidence. Data indicates that the new vaccine significantly decreases urinary tract infections and prevents recurrence in women.
Red Leaf Medical Launches On-Demand Translation Service for CathetersPlus™ Customers
Red Leaf Medical is pleased to announce the launch of a new on-demand translation service available in more than 150 languages to meet the diverse needs of its CathetersPLUS™ customers. The company also introduced new educational tools for nurses following research in support of its CathetersPLUS™ mission to improve the lives of patients who use catheters.
RLM Expands Licensing Agreement with Inmunotek
Through an exclusive licensing agreement, RLM is preparing to bring new vaccines to Canada to prevent recurrent urinary tract infections and recurrent respiratory tract infections. The agreement includes BACTEK™ and UROMUNE™, novel sublingual vaccines.
RLM Launches INSTYLAN™ for Interstitial Cystitis/Painful Bladder Syndrome
Red Leaf Medical is pleased to announce the Canadian launch of INSTYLAN™, a new brand of Hyaluronic Acid (HA) for bladder instillation. INSTYLAN™ is indicated to treat Interstitial Cystitis (IC)/Bladder Pain Syndrome (BPS). Typical symptoms of IC/BPS include pelvic pain, frequency, nocturia, and urgency to urinate.
UROMUNE™ (MV 140) in Recurrent Urinary Tract Infections
A systematic review on the role of UROMUNE™ (MV140) in the prevention of rUTI (recurrent urinary tract infections) has been published. The study, led by Dr. J. Curtis Nickel (Queen's University, Canada), has taken into account published clinical data conducted with this vaccine. UROMUNE (MV140) is a sublingual vaccine developed and manufactured by INMUNOTEK.
Red Leaf Medical Celebrates 10 Years!
Red Leaf Medical thanks its team of dedicated employees for helping to build a leading Canadian healthcare company specializing in the fields of urology and infectious disease. From its founding in 2009, Red Leaf Medical has worked to become a trusted partner to patients and healthcare providers offering industry leading services and patient support programs.
Red Leaf Medical profiled in PharmaBoardroom
Red Leaf Medical, founded in 2009, is unique in its approach to the Canadian healthcare market. Charles Ko, managing director, discusses Red Leaf Medical's foundation, the significance of listening to customers' needs and how a sound domestic reputation can lead to expansive international partnerships.
PROfortil™ Clinically Proven Treatment for Male Infertility Now Available in Canada
Red Leaf Medical is pleased to announce the Canadian launch of PROfortil™, a clinically proven treatment for male fertility disorders that contains a patented composition of micronutrients. According to the Government of Canada Report on Fertility, approximately 16%, or one in six couples, experience infertility…
Red Leaf Medical Enters the Urinary Tract Infection Market
Red Leaf Medical has signed an exclusive Canadian distribution agreement with Inmunotek, a leading pharmaceutical company based in Spain, to commercialize UROMUNE®, a novel sublingual vaccine for the treatment of recurrent urinary tract infection.
Red Leaf Medical Ranks in the PROFIT 500 for Third Year in a Row
Canadian Business and PROFIT unveiled its list of the fastest growing companies and ranked Red Leaf Medical on the 29th annual PROFIT 500, the definitive ranking of Canada’s Fastest-Growing Companies.
Red Leaf Medical Enters the Male Fertility Market
Red Leaf Medical Inc. has signed an exclusive agreement with Lenus Pharma, a leading Austrian pharmaceutical company specializing in fertility, to commercialize PROfortil™ in Canada. PROfortil™ is a clinically proven treatment that contains a patented composition of micronutrients that aid in fertility.
Red Leaf Medical Named One of Canada’s Fastest Growing Companies by Canadian Business Magazine
Canadian Business and PROFIT today listed Red Leaf Medical Inc. on the 28th annual PROFIT 500, the definitive ranking of Canada’s Fastest-Growing Companies.